本文選題：唑來膦酸 + 骨質(zhì)疏松��； 參考：《中國新藥與臨床雜志》2017年08期

【摘要】：目的了解唑來膦酸對(duì)高齡女性骨質(zhì)疏松癥患者骨密度(BMD)和血清骨轉(zhuǎn)換標(biāo)志物(BTMs)的影響。方法納入年齡≥80歲的女性骨質(zhì)疏松癥患者30例,予碳酸鈣D3咀嚼片1片,嚼服,bid;骨化三醇膠丸0.25μg,po,bid。12個(gè)月后予唑來膦酸5 mg靜脈滴注1次,并維持原補(bǔ)鈣和活性維生素D方案。檢測(cè)入組時(shí)、唑來膦酸治療前、治療后12個(gè)月患者血清Ⅰ型膠原交聯(lián)C-末端肽(CTX)、Ⅰ型前膠原N-端前肽(PINP)和骨鈣素(OC)的水平,同時(shí)測(cè)量股骨頸、總髖部和腰椎1-4處的BMD。觀察應(yīng)用唑來膦酸72 h內(nèi)不良反應(yīng)發(fā)生情況。結(jié)果與入組時(shí)比較,唑來膦酸治療前患者血清CTX、PINP和OC水平有所升高,股骨頸、總髖部和腰椎1-4處的BMD有所降低,但大部分指標(biāo)差異無顯著意義(P0.05)。唑來膦酸治療后12個(gè)月,患者血清CTX、PINP和OC水平均明顯低于入組時(shí)和唑來膦酸治療前(P0.05或P0.01),而股骨頸、總髖部和腰椎1-4處的BMD則顯著高于入組時(shí)和唑來膦酸治療前(P0.05或P0.01)。未見嚴(yán)重不良反應(yīng)發(fā)生。結(jié)論唑來膦酸能降低高齡女性骨質(zhì)疏松癥患者的血清BTMs水平,并提高BMD。
[Abstract]:Objective to investigate the effects of zoledronic acid on bone mineral density (BMD) and serum bone turnover markers (BTMs) in elderly women with osteoporosis. Methods Thirty female osteoporosis patients aged more than 80 years were treated with calcium carbonate D3 chewable tablet and chewed with bidbid.Osteotriol colloidal pill 0.25 渭 g popobidbid.12 months later, Zoledronic acid 5mg was given intravenously, and the original calcium supplement and active vitamin D regimen were maintained. Serum levels of type I collagen cross-linked C-terminal peptide (CTX), type 鈪，

本文編號(hào)：2075396